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shows a positive development within the region’s HTA. The Regional Decrees were 
impactful however the HTA reports are not fully compliant to the scoping document 
and it is central to understand the reason behind the challenge.
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Increasingly, quality of life becomes a more important part of the HTA assessments 
of new products. Assessing quality of life is trickier than changes in clinical param-
eters as changes of quality of life tend to occur slower and with a high level of 
variance. Additionally, it is sometimes necessary to assess quality of life indirectly, 
especially in cognitive disorders. However, the available data are often driven by the 
requirements for marketing authorization and rarely fit to the requests of HTA agen-
cies. Quality of life is, among mortality, morbidity and safety, one of the key patient 
relevant outcomes categories in the AMNOG (Arzneimittelmarktneuordnungsgesetz; 
Law on the Reorganization of the Pharmaceutical Market) process in Germany. 
Objectives: Our focus was to review the impact of quality of life data presented 
by manufacturers since the introduction of the AMNOG in 2011 on the level of 
additional benefit claimed by the manufacturer and the evaluation by the Federal 
Joint Committee (G-BA) and the Institute for Quality and Efficiency in Healthcare 
(IQWiG). MethOds: We screened the IMS HTA database and the assessments pub-
lished on the G-BA website for assessments including additional benefit claims 
based on quality of life. We compared these with the corresponding IQWiG reports 
and the final decision of the G-BA (if available). Results: Data on quality of life 
was part of 36 additional benefit claims. In most cases, IQWiG (n= 23) and G-BA 
(n= 28) considered quality of life data as well. However, in 6 cases IQWiG and G-BA 
assessed quality of life, even though the manufacturer didn’t include these data. 
There are only few additional benefit claims acknowledged by G-BA based on qual-
ity of life. cOnclusiOns: Even though quality of life is seen as highly relevant 
factor for the HTA assessment of a new drug or technology, it is rarely taken into 
consideration.
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Objectives: Although subgroup analysis in clinical trials is often criticized, it is still 
considered an important part of the AMNOG Dossier when describing effect modi-
fication in different patient groups. An identification of effect modification in the 
subgroups will either support or weaken the total additional benefit (Zusatznutzen) 
of a drug. The purpose of this article is to give a detailed background with regard to 
the statistical inference in subgroup analysis and a brief review of the effect of tests 
for homogeneity/interactions on the final grading of the additional benefit, accord-
ing to the decision from IQWiG. MethOds: This article covers: Understanding tests 
for homogeneity, individual versus pooled data and influence of subgroup analysis 
on recent IQWiG benefit assessment. A research of the recently published AMNOG 
Dossiers was performed. A description was given to the number of drugs that had 
an additional benefit and the subgroups that were involved. Clustering analysis 
was performed to investigate the hidden structrue in the subgroups. Regression 
models were used to analyze the relationship of the subgroups and the additional 
benefit. Results: Some subgroups such as age, gender and weight play a major role 
in the AMNOG assessment. Other subgroubs are more specific for certain disease 
areas e.g. BMI or hypertension for diabetis. In a worst case the benefit of a drug may 
disappeare when a certain subgroup is taken into consideration. cOnclusiOns: 
Subgroups exert a profound influence upon the overall effect of a drug. Despite of 
the weakness of the statistical inference, subgroup analysis plays an important role 
in the AMNOG Dossier. Some subgroups are frequently related to the overall effect 
of a drug and some might even change the whole story in the AMNOG Dossier. In 
conclusion, subgroup analysis should be understood properly and the results should 
be interpreted carefully.
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Objectives: To index six countries on the basis of the risk they pose to pharma-
ceutical prices with regards to international reference pricing (IRP), from both an 
internal (how IRP is used by the country) and external (how other countries use 
this country for IRP) perspective. MethOds: Details on IRP methodologies were 
obtained from primary and secondary research. Achievable drug price levels in 
Bulgaria, France, Germany, Portugal and Romania were derived from these mar-
kets’ IRP formula and the relative drug price levels in their reference markets 
(based on existing literature). Furthermore, based on the IRP formulas and rela-
tive drug price levels of each of the markets referencing these five and the United 
Kingdom, the markets most likely influenced by the six were identified. This num-
ber of markets, the fraction of them representing major pharmaceutical markets, 
and the relative price levels in each of the six countries were assigned weightings 
to rank them by external risk. Results: While Bulgaria, Portugal and Romania 
represent the greatest internal risk for pharmaceutical prices (i.e. greatest risk of 
obtaining a low price as a result of IRP), these markets fall into the low and moder-
ate risk segments in the external risk index. Conversely, while France, Germany 
and the UK pose the greatest external risk (i.e. as a function of the number of 
significant markets referencing them), they fall into the low and moderate risk seg-
ments in the internal risk index. cOnclusiOns: The inversion seen between the 
two risk indices reflects a key aspect of the current IRP landscape. Namely, mature 
markets exert considerable influence on prices internationally, while their use of 
IRP exerts limited downward pressure on their own prices. Conversely, while IRP 
policy in emerging markets is more likely designed to secure the lowest possible 
prices, these markets carry less influence on prices internationally.
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Objectives: HTA processes are being implemented in Latin America in an effort 
for a more efficient resource allocation. The objective of this study was to explore 
the HTA environment and classify its diversity based on previously developed tax-
onomies. This enables the comparison within the region, as well as with other 
regions in which similar maps have been developed, such as Europe. MethOds: 
Two taxonomic groupings were used as described in Allen et al 2013 Health Policy 
113; 305– 312. The first one is based on the position of a national HTA agency in 
relation to the position of the regulatory and the coverage body. The second set 
focuses on the key tasks performed by the HTA agency. The following countries were 
examined: Mexico, Cuba, Costa Rica, Colombia, Venezuela, Ecuador, Peru, Bolivia, 
Brazil, Uruguay, Argentina and Chile. No information on HTA activity could be iden-
tified for the rest of the countries on official websites or publications. Results: 
Seven different archetypes were identified by combining different values of the two 
taxonomic sets in these twelve countries. There were two main groups identified: 
one consisting of Brazil, Cuba and Chile where the HTA and coverage decisions are 
performed by the same agency and regulatory is independent, and the other one 
consisting of Costa Rica, Venezuela, Peru and Bolivia where no HTA process was 
identified and external evaluations or decisions from reference countries are used 
to inform decisions. cOnclusiOns: Although the landscape is expected to change 
in the coming years, this first high-level overview shows that currently, there is a 
high degree of heterogeneity in HTA processes in Latin America despite the fact 
that these countries tend to share expertise in various levels, with few countries 
following similar processes and a number of countries with no HTA bodies in place 
at any decision level.
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Objectives: The development process of medical devices strongly depends on 
the financial resources available and the expected return on investment to manu-
facturers. The aim of this paper is to analyse the potential commercial viability of 
two disruptive and four incremental medical devices in different stages of develop-
ment. MethOds: The headroom method combined with the return on investment 
analysis was performed for one therapeutic and five diagnostic devices for different 
clinical target areas. Information regarding maximum additional benefit that could 
be obtained with new device, the estimated production price and expected sales 
volume was gathered from literature and expert opinions. A willingness-to-pay 
threshold for one additional QALY of € 30,000 was assumed for headroom analy-
sis. Results: The devices were ranked according to their potential commercial 
viability. The analysis showed that two disruptive and two incremental devices had 
reasonably good balance between headroom and unit cost, and two incremental 
devices had no good balance. The device with the highest potential commercial 
viability was a disruptive therapeutic device for the cartilage repair treatment 
in the first clinical trial stage, with estimated headroom for the cost of the new 
treatment: € 74,600 and an expected production cost of the therapy: € 8,000 per unit. 
The market volume size was calculated based on the incidence of cartilage defects: 
65% in routine knee arthroscopies. The disruptive diagnostic device for home brain 
monitoring of epilepsy patients in the prototype stage of development had the low-
est potential commercial viability, with an estimated headroom of € 81,000 and an 
expected production costs per unit: € 120,000 that resulted in the unfavorable return 
on investment. cOnclusiOns: The headroom method combined with a return on 
investment analysis, offers insight in the potential commercial viability of medical 
devices under development. The research on the impact of that analysis on actual 
R&D decision making will still be determined.
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Objectives: Data availability and decision makers methodology requirements are 
two important factors influencing transferability of economic studies. Applying quali-
tative assessment of experts’ opinion and systematic review of published economic 
studies, we aimed to analyze transferability of economic evaluations in Central and 
Eastern European (CEE) and former Soviet countries. MethOds: Firstly, eleven reim-
bursement experts from eight countries were interviewed on their background and 
current practice of using economic evaluations, opinion regarding transferability 
of economic evaluations and importance of individual Welte’s transferability fac-
tors. Secondly, we analyzed peer-reviewed English-language economic evaluations 
